» Authors » Marek Harhala

Marek Harhala

Explore the profile of Marek Harhala including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 434
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Szewczyk-Dabrowska A, Budziar W, Harhala M, Baniecki K, Pikies A, Jedruchniewicz N, et al.
Sci Rep . 2022 Sep; 12(1):15944. PMID: 36153350
Predictors for the risk of severe COVID-19 are crucial for patient care and control of the disease. Other infectious diseases as potential comorbidities in SARS-CoV-2 infection are still poorly understood....
2.
Hodyra-Stefaniak K, Kazmierczak Z, Majewska J, Sillankorva S, Miernikiewicz P, Miedzybrodzki R, et al.
Phage (New Rochelle) . 2022 Sep; 1(2):91-99. PMID: 36147897
Bacteriophages may induce specific antibodies after natural exposure to phages or after phage therapy. As such, phage-specific antibodies might impact phage bioavailability , although limited non-neutralizing or insignificant effects have...
3.
Szewczyk-Dabrowska A, Budziar W, Baniecki K, Pikies A, Harhala M, Jedruchniewicz N, et al.
PLoS One . 2022 Sep; 17(9):e0274095. PMID: 36083875
The immune response and specific antibody production in COVID-19 are among the key factors that determine both prognostics for individual patients and the global perspective for controlling the pandemics. So...
4.
Cieslik M, Harhala M, Orwat F, Dabrowska K, Gorski A, Jonczyk-Matysiak E
Viruses . 2022 Jul; 14(7). PMID: 35891499
In an era of antibiotic therapy crisis caused by spreading antimicrobial resistance, and when recurrent urinary tract infections constitute a serious social and medical problem, the isolation and complex characterization...
5.
Budziar W, Gembara K, Harhala M, Szymczak A, Jedruchniewicz N, Baniecki K, et al.
PLoS One . 2022 Feb; 17(2):e0253638. PMID: 35113873
Population immunity (herd immunity) to SARS-CoV-2 derives from two sources: vaccinations or cases of infection with the virus. Infections can be diagnosed as COVID-19 and registered, or they can be...
6.
Harhala M, Gembara K, Miernikiewicz P, Owczarek B, Kazmierczak Z, Majewska J, et al.
Front Microbiol . 2021 Nov; 12:752282. PMID: 34759903
Increasing number of deaths from multi-drug resistant bacterial infections has caused both the World Health Organization and the Centers for Disease Control and Prevention to repeatedly call for development of...
7.
Kazmierczak Z, Majewska J, Miernikiewicz P, Miedzybrodzki R, Nowak S, Harhala M, et al.
Front Immunol . 2021 Jul; 12:639570. PMID: 34194425
Bacteriophages are able to affect the human immune system. Phage-specific antibodies are considered as major factors shaping phage pharmacokinetics and bioavailability. So far, general knowledge of phage antigenicity nevertheless remains...
8.
Majewska J, Kazmierczak Z, Lahutta K, Lecion D, Szymczak A, Miernikiewicz P, et al.
Front Immunol . 2019 Dec; 10:2607. PMID: 31803179
In therapeutic phage applications oral administration is a common and well-accepted delivery route. Phages applied may elicit a specific humoral response, which may in turn affect phage activity. We present...
9.
Hodyra-Stefaniak K, Lahutta K, Majewska J, Kazmierczak Z, Lecion D, Harhala M, et al.
Microb Biotechnol . 2019 May; 12(4):730-741. PMID: 31037835
Bacteriophages draw scientific attention in medicine and biotechnology, including phage engineering, widely used to shape biological properties of bacteriophages. We developed engineered T4-derived bacteriophages presenting seven types of tissue-homing peptides....
10.
Harhala M, Nelson D, Miernikiewicz P, Heselpoth R, Brzezicka B, Majewska J, et al.
Viruses . 2018 Nov; 10(11). PMID: 30445722
Bacteriophage-derived endolysins have gained increasing attention as potent antimicrobial agents and numerous publications document the in vivo efficacy of these enzymes in various rodent models. However, little has been documented...